Hostname: page-component-586b7cd67f-2plfb Total loading time: 0 Render date: 2024-11-26T02:57:45.589Z Has data issue: false hasContentIssue false
  • English
  • Français

A neuroscientific update on monoamine oxidase and its inhibitors

Published online by Cambridge University Press:  19 November 2013

Thomas L. Schwartz
Thomas L. Schwartz*
Affiliation:
Psychiatry Department, SUNY Upstate Medical University, Syracuse, New York, USA
*
*Address for correspondence: Thomas L. Schwartz. (Email: [email protected])
Get access Rights & Permissions [Opens in a new window]

Abstract

The goal of this brief review is to explain the role of monoamine oxidase enzymes in the neurobiology, etiology, and presentation of psychiatric illnesses, primarily major depressive disorder. This article will initially focus on the basic science and function of the monoamine oxidase system and some proposed neuropsychiatric symptoms that may arise if this enzyme system is altered by genetic predisposition. These findings and theories will next be translationally discussed in regard to clinical application pertaining to enzyme inhibition and the treatment of major depressive and other psychiatric disorders.

Keywords

Antidepressant treatmentmajor depressive disordermonoamine oxidase inhibition
Type
CME Review Article
Information
CNS Spectrums , Volume 18 , Issue s1: CME SUPPLEMENT , December 2013 , pp. 22 - 33
Copyright
Copyright © Cambridge University Press 2013 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Footnotes

This activity is supported by an educational grant from Mylan Specialty L.P.

References

1.Lacasse, JR, Leo, J. Serotonin and depression: a disconnect between the advertisements and the scientific literature. PLoS Med. 2005; 2: e392.CrossRefGoogle ScholarPubMed
2.Belmaker, RH, Agam, G. Major depressive disorder. N Engl J Med. 2008; 358: 55–68.CrossRefGoogle ScholarPubMed
3.Stahl, SM. Stahl's Essential Psychopharmacology: Neuroscientific Basis and Practical Application, 4th ed.Cambridge, UK: Cambridge University Press; 2013.Google Scholar
4.Sadock, BJ, Sadock, VA, Sussman, N. Kaplan & Sadock's Pocket Handbook of Psychiatric Drug Treatment, 5th ed.Philadelphia: Lippincott, Williams & Wilkins; 2011.Google Scholar
5.Stahl, SM. Stahl's Essential Psychopharmacology: The Prescriber's Guide, 4th ed.Cambridge, UK: Cambridge University Press; 2011.CrossRefGoogle Scholar
6.Berlim, MT, Fleck, MP, Turecki, G. Current trends in the assessment and somatic treatment of resistant/refractory major depression: an overview. Ann Med. 2008; 40(2): 149–159.CrossRefGoogle ScholarPubMed
7.Greden, JF. The burden of recurrent depression: causes, consequences, and future prospects. J Clin Psychiatry. 2001; 62(Suppl 22): 5–9.Google ScholarPubMed
8.Kessler, RC, Berglund, P, Demler, O, etal. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA. 2003; 289(23): 3095–3105.CrossRefGoogle ScholarPubMed
9.Keller, MB, Boland, RJ. Implications of failing to achieve successful long-term maintenance treatment of recurrent unipolar major depression. Biol Psychiatry. 1998; 44(5): 348–360.CrossRefGoogle ScholarPubMed
10.Keller, MB, Shapiro, RW. “Double depression”: superimposition of acute depressive episodes on chronic depressive disorders. Am J Psychiatry. 1982; 139(4): 438–442.Google ScholarPubMed
11.Mueller, TI, Leon, AC. Recovery, chronicity, and levels of psychopathology in major depression. Psychiatr Clin North Am. 1996; 19(1): 85–102.CrossRefGoogle ScholarPubMed
12.Fava, M, Rush, AJ, Trivedi, MH, etal. Background and rationale for the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study. Psychiatr Clin North Am. 2003; 26(2): 457–494; x.CrossRefGoogle ScholarPubMed
13.Murrough, JW, Charney, DS. Is there anything really novel on the antidepressant horizon? Curr Psychiatry Rep. 2012; 14(6): 643–649.CrossRefGoogle ScholarPubMed
14.Schwartz, TL, Stahl, SM. Optimizing antidepressant management of depression: current status and future perspectives. In Cryan JF, Leonard BE, eds. Depression: From Psychopathology to Pharmacotherapy. Vol. 27. Basel, Switzerland: Karger; 2010: 54–67.Google Scholar
15.Sacher, J, Rabiner, EA, Clark, M, etal. Dynamic, adaptive changes in MAO-A binding after alterations in substrate availability: an in vivo [(11)C]-harmine positron emission tomography study. J Cereb Blood Flow Metab. 2012; 32(3): 443–446.CrossRefGoogle Scholar
16.Howes, OD, Kapur, S. The dopamine hypothesis of schizophrenia: version III—the final common pathway. Schizophr Bull. 2009; 35(3): 549–562.CrossRefGoogle ScholarPubMed
17.Du, L, Faludi, G, Pakovits, M, etal. High activity-related allele of MAO-A gene associated with depressed suicide in males. Neuroreport. 2002; 13: 1195–1198.CrossRefGoogle ScholarPubMed
18.De Luca, V, Tharmalingam, S, Sicard, T, Kennedy, JL. Gene-gene interaction between MAOA and COMT in suicidal behavior. Neurosci Lett. 2005; 383(1–2): 151–154.Google ScholarPubMed
19.Johnson, S, Stockmeier, CA, Meyer, JH, etal. The reduction of R1, a novel repressor protein for monoamine oxidase A, in major depressive disorder. Neuropsychopharmacology. 2011; 36(10): 2139–2148.CrossRefGoogle ScholarPubMed
20.Meyer, JH. Neuroimaging markers of cellular function in major depressive disorder: implications for therapeutics, personalized medicine, and prevention. Clin Pharmacol Ther. 2012; 91(2): 201–214.CrossRefGoogle ScholarPubMed
21.Meyer, JH, Wilson, AA, Sagrati, S, etal. Brain monoamine oxidase A binding in major depressive disorder: relationship to selective serotonin reuptake inhibitor treatment, recovery, and recurrence. Arch Gen Psychiatry. 2009; 66(12): 1304–1312.CrossRefGoogle ScholarPubMed
22.Rush, AJ, Trivedi, MH, Wisniewski, SR, etal. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006; 163(11): 1905–1917.CrossRefGoogle ScholarPubMed
23.Zajecka, JM, Goldstein, C. Combining medications to achieve remission. In Schwartz TL, Petersen TJ, eds. Depression: Treatment Strategies and Management, 2nd Ed.New York: Informa; 2010; 54–100.Google Scholar
24.Pitychoutis, PM, Zisaki, A, Dalla, C, Papadopoulou-Daifoti, Z. Pharmacogenetic insights into depression and antidepressant response: does sex matter? Curr Pharm Des. 2010; 16(20): 2214–2223.CrossRefGoogle ScholarPubMed
25.Fan, M, Liu, B, Jiang, T, etal. Meta-analysis of the association between the monoamine oxidase-A gene and mood disorders. Psychiatr Genet. 2010; 20(1): 1–7.CrossRefGoogle ScholarPubMed
26.Gutiérrez, B, Arias, B, Gastó, C, etal. Association analysis between a functional polymorphism in the monoamine oxidase A gene promoter and severe mood disorders. Psychiatr Genet. 2004; 14(4): 203–208.CrossRefGoogle ScholarPubMed
27.Kinnally, EL, Huang, YY, Haverly, R, etal. Parental care moderates the influence of MAOA-uVNTR genotype and childhood stressors on trait impulsivity and aggression in adult women. Psychiatr Genet. 2009; 19(3): 126–133.CrossRefGoogle ScholarPubMed
28.Lung, FW, Tzeng, DS, Huang, MF, Lee, MB. Association of the MAOA promoter uVNTR polymorphism with suicide attempts in patients with major depressive disorder. BMC Med Genet. 2011; 12: 74.CrossRefGoogle ScholarPubMed
29.Schulze, TG, Müller, DJ, Krauss, H, etal. Association between a functional polymorphism in the monoamine oxidase A gene promoter and major depressive disorder. Am J Med Genet. 2000; 96(6): 801–803.3.0.CO;2-4>CrossRefGoogle ScholarPubMed
30.Xu, Z, Zhang, Z, Shi, Y, etal. Influence and interaction of genetic polymorphisms in catecholamine neurotransmitter systems and early life stress on antidepressant drug response. J Affect Disord. 2011; 133(1–2): 165–173.CrossRefGoogle ScholarPubMed
31.Buckholtz, JW, Callicott, JH, Kolachana, B, etal. Genetic variation in MAOA modulates ventromedial prefrontal circuitry mediating individual differences in human personality. Mol Psychiatry. 2008; 13(3): 313–324.CrossRefGoogle ScholarPubMed
32.Schwartz, TL. Psychopharmacological practice: the DSM versus the brain. Mens Sana Monogr. 2013; 11(1): 25–41.CrossRefGoogle ScholarPubMed
33.Bremner, JD, Narayan, M, Anderson, ER, etal. Hippocampal volume reduction in major depression. Am J Psychiatry. 2000; 157(1): 115–118.CrossRefGoogle ScholarPubMed
34.Sheline, YI, Sanghavi, M, Mintun, MA, Gado, MH. Depression duration but not age predicts hippocampal volume loss in medically healthy women with recurrent major depression. J Neurosci. 1999; 19(12): 5034–5043.CrossRefGoogle Scholar
35.Andreazza, AC, Shao, L, Wang, JF, Young, LT. Mitochondrial complex I activity and oxidative damage to mitochondrial proteins in the prefrontal cortex of patients with bipolar disorder. Arch Gen Psychiatry. 2010; 67(4): 360–368.CrossRefGoogle ScholarPubMed
36.Thalmeier, A, Dickmann, M, Giegling, I, etal. Gene expression profiling of post-mortem orbitofrontal cortex in violent suicide victims. Int J Neuropsychopharmacol. 2008; 11(2): 217–228.CrossRefGoogle ScholarPubMed
37.Sacher, J, Wilson, AA, Houle, S, etal. Elevated brain monoamine oxidase A binding in the early postpartum period. Arch Gen Psychiatry. 2010; 67(5): 468–474.CrossRefGoogle ScholarPubMed
38.Keating, C, Tilbrook, A, Kulkarni, J. Oestrogen: an overlooked mediator in the neuropsychopharmacology of treatment response? Int J Neuropsychopharmacol. 2011; 14(4): 553–566.CrossRefGoogle ScholarPubMed
39.Meyers, B, D'Agostino, A, Walker, J, Kritzer, MF. Gonadectomy and hormone replacement exert region- and enzyme isoform-specific effects on monoamine oxidase and catechol-O-methyltransferase activity in prefrontal cortex and neostriatum of adult male rats. Neuroscience. 2010; 165(3): 850–862.CrossRefGoogle ScholarPubMed
40.Wu, JB, Chen, K, Li, Y, Lau, YF, Shih, JC. Regulation of monoamine oxidase A by the SRY gene on the Y chromosome. FASEB J. 2009; 23(11): 4029–4038.CrossRefGoogle ScholarPubMed
41.Schwartz, TL. Introduction to the special issue focused on the future or psychopharmacological practice. Clinical Neuropsychiatry. 2011; 8(1): 3.Google Scholar
42.Garriock, HA, Moreno, FA. Genetics of depression: implications for clinical practice yet? Clinical Neuropsychiatry. 2011; 8(1): 37–46.Google Scholar
43.Gillman, PK. Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity. Br J Anaesth. 2005; 95(4): 434–441.CrossRefGoogle ScholarPubMed
44.Stahl, SM, Felker, A. Monoamine oxidase inhibitors: a modern guide to an unrequited class of antidepressants. CNS Spectr. 2008; 13(10): 855–870.CrossRefGoogle Scholar
45.Ansari, J. Drug interaction and pharmacist. J Young Pharm. 2010; 2(3): 326–331.CrossRefGoogle ScholarPubMed